Mostrar el registro sencillo del ítem
Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
dc.contributor.author | Perez-Lloret S. | |
dc.contributor.author | Otero-Losada M. | |
dc.contributor.author | Toblli J.E. | |
dc.contributor.author | Capani F. | |
dc.date.accessioned | 2020-09-02T22:25:47Z | |
dc.date.available | 2020-09-02T22:25:47Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1080/13543784.2017.1371133 | |
dc.identifier.citation | 26, 10, 1163-1173 | |
dc.identifier.issn | 13543784 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/5777 | |
dc.description | Introduction: Currently, available therapies for Parkinson’s disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability. Neuroprotective effects in animal PD models have been shown for the angiotensin-converting enzyme (ACE) inhibitors captopril and perindopril, and the AT1 receptor antagonists losartan, candesartan and telmisartan. These effects appear to be mediated by a reduction in the overproduction of reactive oxygen species. In a proof-of-concept, randomized, double-blind, crossover study in PD patients, perindopril enhanced the effect of levodopa without inducing dyskinesias. There has not been any clinical trial exploring the neuroprotective effect of RAS drugs, but one cohort study in hypertensive patients suggested a protective effect of ACE inhibitors on PD risk. RAS is a promising target for symptomatic and neuroprotective therapies in PD. Further studies in PD animal models and patients are warranted. © 2017 Informa UK Limited, trading as Taylor & Francis Group. | |
dc.language.iso | en | |
dc.publisher | Taylor and Francis Ltd | |
dc.subject | angiotensin | |
dc.subject | neuroprotection | |
dc.subject | Parkinson’s disease | |
dc.subject | renin | |
dc.subject | treatment | |
dc.subject | angiotensin 1 receptor antagonist | |
dc.subject | angiotensin II | |
dc.subject | angiotensin receptor | |
dc.subject | dipeptidyl carboxypeptidase inhibitor | |
dc.subject | dopamine | |
dc.subject | levodopa | |
dc.subject | reactive oxygen metabolite | |
dc.subject | angiotensin 1 receptor antagonist | |
dc.subject | antiparkinson agent | |
dc.subject | dipeptidyl carboxypeptidase inhibitor | |
dc.subject | dopamine | |
dc.subject | neuroprotective agent | |
dc.subject | reactive oxygen metabolite | |
dc.subject | brain region | |
dc.subject | dopaminergic nerve cell | |
dc.subject | drug effect | |
dc.subject | drug targeting | |
dc.subject | human | |
dc.subject | levodopa-induced dyskinesia | |
dc.subject | nerve degeneration | |
dc.subject | neuroprotection | |
dc.subject | nonhuman | |
dc.subject | Parkinson disease | |
dc.subject | renin angiotensin aldosterone system | |
dc.subject | Review | |
dc.subject | animal | |
dc.subject | drug design | |
dc.subject | drug effects | |
dc.subject | metabolism | |
dc.subject | molecularly targeted therapy | |
dc.subject | Parkinson disease | |
dc.subject | pathophysiology | |
dc.subject | randomized controlled trial (topic) | |
dc.subject | renin angiotensin aldosterone system | |
dc.subject | Angiotensin II Type 1 Receptor Blockers | |
dc.subject | Angiotensin-Converting Enzyme Inhibitors | |
dc.subject | Animals | |
dc.subject | Antiparkinson Agents | |
dc.subject | Dopamine | |
dc.subject | Drug Design | |
dc.subject | Humans | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Neuroprotective Agents | |
dc.subject | Parkinson Disease | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.subject | Reactive Oxygen Species | |
dc.subject | Renin-Angiotensin System | |
dc.title | Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease | |
dc.type | Review |